Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9630513 | 0.94 | NR4A2 (0.39) | NR4A2KCNH2TP53SOS1MKNK1 | |
| Hydrochloric Acid SCHEMBL9630572 | 0.93 | NR4A2 (0.39) | NR4A2KCNH2TP53SOS1MKNK1 | |
| Oxalic Acid SCHEMBL9629525 | 0.91 | MEN1 (0.40) | NR4A2KCNH2TP53SOS1MEN1 | |
| Oxalic Acid SCHEMBL9629530 | 0.91 | MEN1 (0.40) | NR4A2KCNH2TP53SOS1MEN1 | |
| SCHEMBL9876866 | 0.90 | NR4A2 (0.45) | NR4A2KCNH2TP53SOS1MKNK1 | |
| Oxalic Acid SCHEMBL9630341 | 0.89 | MEN1 (0.40) | NR4A2KCNH2TP53MKNK1MEN1 | |
| Oxalic Acid SCHEMBL9630351 | 0.89 | MEN1 (0.40) | NR4A2KCNH2TP53MKNK1MEN1 | |
| Noberastine SCHEMBL1230647 | 0.88 | NR4A2 (0.37) | NR4A2KCNH2TP53SOS1MEN1 | |
| Hydrochloric Acid SCHEMBL9876566 | 0.88 | TP53 (0.45) | NR4A2KCNH2TP53SOS1MKNK1 | |
| SCHEMBL9687066 | 0.88 | RET (0.39) | TP53MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1753 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2913062-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY AND METHOD OF TESTING FOR RETINOPATHY OF PREMATURITY | JAPAN INNOVATIVE THERAPEUTICS INC (JP) | 2019-05-08 | — | — | EP | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014134005-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-08-28 | — | — | US | claimed |
| CN-101486668-B | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC | 2014-07-02 | — | — | CN | claimed |
| US-8758816-B2 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2014-06-24 | — | — | US | claimed |
| EP-2173169-B1 | NASAL DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CYDEX PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | claimed |
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | claimed |
| EP-0920315-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1999-06-09 | — | — | EP | claimed |
| US-5869479-A | ADMINISTERING HISTAMINE H1 RECEPTOR ANTAGONISTS AND HISTAMINE H3 RECEPTOR ANTAGONISTS; NASAL DECONGESTANT WITHOUT THE NERVOUS SYSTEM OR CARDIOVASCULAR SIDE EFFECTS | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | claimed |
| WO-1998006394-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-19 | — | — | WO | claimed |
| EP-0464927-B1 | 3-[(5-Methyl-2-furanyl)methyl]-N-(4-piperidinyl)-3H-imidazo[4,5-b]-pyridin-2-amine 2-hydroxy-1,2,3-propanetricarboxylate | JANSSEN PHARMACEUTICA NV (BE) | 1996-09-04 | — | — | EP | claimed |
| CN-1026790-C | Noberastine citrate | JANSSEN PHARMACEUTICA NV (BE) | 1994-11-30 | — | — | CN | claimed |
| EP-0232937-B1 | ANTI-HISTAMINIC COMPOSITIONS CONTAINING N-HETEROCYCLYL-4-PIPERIDINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-19 | — | — | EP | claimed |
| CN-1058020-A | NOBERASTINE CITRATE | JANSSEN PHARMACEUTICA NV (BE) | 1992-01-22 | — | — | CN | claimed |
| EP-0464927-A2 | 3-[(5-Methyl-2-furanyl)methyl]-N-(4-piperidinyl)-3H-imidazo[4,5-b]-pyridin-2-amine 2-hydroxy-1,2,3-propanetricarboxylate | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-01-08 | — | — | EP | claimed |
| US-4835161-A | Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-30 | — | — | US | claimed |
| EP-0232937-A2 | Anti-histaminic compositions containing N-heterocyclyl-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-08-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | NR4A2 3993/4885KCNH2 908/4885TP53 3789/4885 |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | NR4A2 3993/4885KCNH2 908/4885TP53 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.